FindTrial
Sign In

Platinum-Based Drug

DRUG6 trials

Sponsors

Canadian Cancer Trials Group, Chinese Academy of Medical Sciences, Blokhin's Russian Cancer Research Center, Zhejiang Cancer Hospital

Conditions

BRCA1 MutationBRCA2 MutationChemotherapyEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaIMRT With or Without Concurrent Chemotherapy for Esophageal CancerLung Cancer MetastaticNon-small Cell Lung Cancer Stage III

Phase 2

Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC
Active, not recruitingNCT03057106
Canadian Cancer Trials GroupLung Cancer Metastatic
Start: 2017-03-28End: 2026-06-30Updated: 2026-03-03
Efficacy of Platinum-based Chemotherapy in Platinum-resistant Ovarian Cancer) (EPITOC)
NCT04055038
Blokhin's Russian Cancer Research CenterBRCA1 Mutation, BRCA2 Mutation, Chemotherapy +3
Start: 2019-09-01End: 2022-01-01Target: 164Updated: 2019-08-13
A Study of Toripalimab Combined With Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma.
SuspendedNCT04084158
Zhejiang Cancer HospitalEsophageal Squamous Cell Carcinoma
Start: 2019-09-07End: 2021-12-30Target: 100Updated: 2021-02-23

Phase 3

Radiotherapy With or Without Concurrent Chemotherapy for Limited Lymphatic Metastasis of Esophageal Cancer - 3JECROG P-02
NCT03308552
Chinese Academy of Medical SciencesEsophageal Neoplasms
Start: 2017-12-01End: 2021-08-30Target: 164Updated: 2019-01-02
Radiotherapy With or Without Concurrent Chemotherapy for Extensive Lymphatic Metastasis of Esophageal Cancer - 3JECROG P-03
NCT03328234
Chinese Academy of Medical SciencesIMRT With or Without Concurrent Chemotherapy for Esophageal Cancer
Start: 2017-09-01End: 2022-12-31Target: 2Updated: 2019-01-02
Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy
NCT06031597
Zhejiang Cancer HospitalNon-small Cell Lung Cancer Stage III
Start: 2023-09-15End: 2025-12-31Target: 105Updated: 2023-09-13

Related Papers

Comparing toripalimab combined with chemoradiotherapy versus chemoradiotherapy alone for locally advanced esophageal squamous cell carcinoma: A multicenter, open-label, randomized phase II clinical trial.
Journal of Clinical Oncology2024-06-01
Effect of bone metastasis on outcomes in the CCTG BR.34 phase II randomized trial of dual immune checkpoint inhibitor (ICI) treatment with or without chemotherapy in high-risk, stage IVA/B NSCLC.
Journal of Clinical Oncology2022-06-012 citations
A multicenter prospective phase III clinical randomized study of simultaneous integrated boost intensity-modulated radiotherapy with or without concurrent chemotherapy in patients with esophageal cancer: 3JECROG P-02 study protocol.
2020-09-2210 citations
CCTG BR.34: A randomized trial of durvalumab and tremelimumab +/- platinum-based chemotherapy in patients with metastatic (Stage IV) squamous or nonsquamous non-small cell lung cancer (NSCLC).
Journal of Clinical Oncology2020-05-2026 citations
A phase I/II radiation dose escalation trial using simultaneous integrated boost technique with elective nodal irradiation and concurrent chemotherapy for unresectable esophageal Cancer
Radiation Oncology2019-03-1534 citations